Andrew Blauvelt
Experienced in Autosomal Recessive Hypotrichosis

Dr. Andrew Blauvelt

Dermatology
James W. Baker MD LLC
9495 SW Locust St Ste A, 
Portland, OR 
Experienced in Autosomal Recessive Hypotrichosis
James W. Baker MD LLC
9495 SW Locust St Ste A, 
Portland, OR 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Andrew Blauvelt is a Dermatologist in Portland, Oregon. Dr. Blauvelt is rated as an Experienced provider by MediFind in the treatment of Autosomal Recessive Hypotrichosis. His top areas of expertise are Plaque Psoriasis, Psoriasis, Atopic Dermatitis, and Actinic Keratosis.

His clinical research consists of co-authoring 308 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 1 clinical trial in the study of Autosomal Recessive Hypotrichosis.

Specialties
Dermatology
Licenses
Dermatology in OR
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Moda Health
  • EPO
  • PPO

Locations

James W. Baker MD LLC
9495 SW Locust St Ste A, Portland, OR 97223

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Enrollment Status: Completed
Publish Date: November 05, 2025
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
Decreasing Resident Memory T Cells While Increasing Clinical Durability: Higher Induction Doses of Risankizumab for Moderate-to-severe Plaque Psoriasis
Decreasing Resident Memory T Cells While Increasing Clinical Durability: Higher Induction Doses of Risankizumab for Moderate-to-severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: October 24, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
Enrollment Status: Completed
Publish Date: October 01, 2025
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 2/Phase 3
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Drug
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
Enrollment Status: Terminated
Publish Date: March 21, 2023
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: November 30, 2022
Intervention Type: Biological, Other
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Phase IV, Open Label Study of the Effects of Apremilast on Vascular Inflammation and Cardiometabolic Function in Psoriasis
A Phase IV, Open Label Study of the Effects of Apremilast on Vascular Inflammation and Cardiometabolic Function in Psoriasis
Enrollment Status: Completed
Publish Date: November 10, 2022
Intervention Type: Drug
Study Drug: Apremilast
Study Phase: Phase 4
A Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy and Safety of Lebrikizumab When Used In Combination With Topical Corticosteroid Treatment In Patients With Moderate-To-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy and Safety of Lebrikizumab When Used In Combination With Topical Corticosteroid Treatment In Patients With Moderate-To-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: May 09, 2022
Intervention Type: Other, Biological
Study Drugs: Lebrikizumab, Topical Corticosteroid
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: May 04, 2021
Intervention Type: Drug, Biological
Study Phase: Phase 2
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Withdrawal Maintenance Dosing Period to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-1
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Withdrawal Maintenance Dosing Period to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-1
Enrollment Status: Completed
Publish Date: September 25, 2020
Intervention Type: Drug
Study Phase: Phase 3
A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: July 28, 2020
Intervention Type: Drug
Study Phase: Phase 4
A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris)
A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris)
Enrollment Status: Completed
Publish Date: June 04, 2019
Intervention Type: Other, Biological
Study Phase: Phase 2
View 11 Less Clinical Trials

308 Total Publications

Moderate-to-severe atopic dermatitis and systemic corticosteroids are associated with insulin resistance and metabolic syndrome.
Moderate-to-severe atopic dermatitis and systemic corticosteroids are associated with insulin resistance and metabolic syndrome.
Journal: JAAD international
Published: December 16, 2025
Similar Doctors
Distinguished in Autosomal Recessive Hypotrichosis
Dr. Janet Roberts
Dermatology
Distinguished in Autosomal Recessive Hypotrichosis
Dr. Janet Roberts
Dermatology

Oregon Adult Medicine PC

2330 NW Flanders St Ste 201, 
Portland, OR 
 (7.1 miles away)
503-223-1933
Languages Spoken:
English
See accepted insurances

Janet Roberts is a Dermatologist in Portland, Oregon. Dr. Roberts is rated as an Advanced provider by MediFind in the treatment of Autosomal Recessive Hypotrichosis. Her top areas of expertise are Graham-Little-Piccardi-Lassueur Syndrome, Autosomal Recessive Hypotrichosis, Alopecia Areata, and Female Pattern Baldness.

Advanced in Autosomal Recessive Hypotrichosis
Dr. Janelle Rohrback
Dermatology
Advanced in Autosomal Recessive Hypotrichosis
Dr. Janelle Rohrback
Dermatology

Providence St Vincent Heart Clinics Cardiology Portland Clinic Beavert

15950 SW Millikan Way, 
Beaverton, OR 
 (4.5 miles away)
503-646-0161
Languages Spoken:
English
See accepted insurances

Janelle Rohrback is a Dermatologist in Beaverton, Oregon. Dr. Rohrback is rated as an Advanced provider by MediFind in the treatment of Autosomal Recessive Hypotrichosis. Her top areas of expertise are Actinic Keratosis, Warts, Seborrheic Keratosis, and Sunburn.

Advanced in Autosomal Recessive Hypotrichosis
Dr. Nisha Desai
Dermatology
Advanced in Autosomal Recessive Hypotrichosis
Dr. Nisha Desai
Dermatology

NW. Dermatology And Research Center LLC

2525 NW Lovejoy St Ste 400, 
Portland, OR 
 (7.1 miles away)
503-223-1933
Languages Spoken:
English
See accepted insurances

Nisha Desai is a Dermatologist in Portland, Oregon. Dr. Desai is rated as a Distinguished provider by MediFind in the treatment of Autosomal Recessive Hypotrichosis. Her top areas of expertise are Graham-Little-Piccardi-Lassueur Syndrome, Malignant Hypertension, Female Pattern Baldness, and Melanoma.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Blauvelt's expertise for a condition
ConditionClose
    View All 11 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile